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Summary. Rabbit anti-mouse tumour cell serum can be made tumour specific
by absorption with normal mouse cells and in an in vivo protection test can be shown
to have a measurable protective effect on mice against a given number of lethal doses
of a lymphoma. Some drugs have been evaluated in this system. When drug
treatment is combined with antibody treatment much greater protection can be
obtained than when the same amounts of drug or antibody are used alone. It is
preferable to administer drug before antibody and with the combined schedule it is
possible in the test model to protect all mice from tumour growth, even allowing the
tumour up to 48 h " get-away " time before starting treatment.
IN A previous paper (Davies, Manstone
and Buckham, 1974b) we described some
features of the protection of mice against
leukaemias by using in vitro absorbed
xeno-anti-tumour immunoglobulin; this
particular design can be used to answer
questions of clinical relevance because
the reagent can be obtained in a similar
way for human patients.
The test system is the protection of
C57BL/6 mice against the carcinogen
induced lymphoma EL4 with tumour
specific immunoglobulin prepared from
rabbit antiserum. This is a versatile
system which has been used by many
workers previously in various forms. It
can be adjusted to greater sensitivity
by (a) limiting the challenge dose of
tumour cells, (b) reducing the time lapse
between challenge and treatment and
(c) giving multiple treatment doses of (d)
greater amounts of putative therapeutic
material. The test system can be made
more severe by taking the reverse of any
of these measures, as has been done for
the tests described in this paper. Thus,
for example, the amplification of the
effect of antiserum treatment by drugs
as described below has necessitated in-
creasing the time lapse between challenge
and treatment from 2 h to 96 h, otherwise
protection would have been total and
nothing learned about further possible
improvements.
Tumour specific antibodies alone are
not able to reverse the continuing growth
of well established tumours in clinical
practice, but our results (Davies and
O'Neill, 1973; Davies et al., 1974b) hinted
at a synergistic effect between drugs and
antibodies. This topic is expanded upon
in the present paper, because the combined
effect might be capable of tipping the
balance in a patient's favour.
MATERIALS AND METHODS
Biological.-These were described in some
detail in our previous paper (Davies et al.,
1974b) and can be summarized as follows.
Rabbits were immunized by 3 injections at
10 day intervals of 108 live EL4 cells (grown
in C57BL/6 mice) and bled 10 days later.
The serum was heat inactivated at 56°C for
30 min and absorbed with mouse spleen
cells until the complement mediated cyto-
toxic titre (rabbit complement and a 3 h
incubation period) for normal C57BL/6
lymph node cells was reduced to zero. This
generally required about 3000 to 5000
spleens per 100 ml of serum. This serum
retained a small cytotoxic activity for EL4D. A. L. DAVIES, S. BUCKHAM AND A. J. MANSTONE
target cells, best revealed by neuraminidase
pretreatment of the target cells (Davies and
O'Neill, 1973). The sera (in some eases
fractionated to Ig with ammonium sulphate)
were used in protection tests where groups
of C57BL/6 mice (5-15 in each group,
depending on availability of serum) were
challenged with 105 EL4 cells i.p. (or 5 x 104
in some instances). The mice were treated
by 4 injections on 4 successive days with
Ig alone, drug alone, or both together, to
protect them from death by tumour growth
or to prolong their lives. The time lapse
between challenge and the first injection
differed in different tests, as is indicated
below.
Chemical.-Chlorambucil B.P. and mel-
phalan B.P. (Alkeran) were obtained from
Burroughs Wellcome & Co., London. Cyclo-
phosphamide (Endoxana) was obtained from
Ward Blenkinsop and Co., London.
RESULTS
Toxicity of drugs used
The direct toxicity of the 3 drugs
used in these experiments, in single and
repeated doses, was measured by i.p.
injection in mice and some results for
melphalan are shown as an example in
Table (a). There was severe weight loss
in survivors given marginally sub-lethal
doses and usable doses are shown in
Table (b). The " safe " dose was about
halfofthe lower usable range.
TABLE. The Toxicity and Suitable Dose
Ranges of some Nitrogen Muustards*
(a)
Dose of
melphalan
(jUg)
750
500
250
100
Deaths of mice
(from group of 5)
and day of clemise
5 (Day 3)
3 (Day 5), 5 (by Day 9)
2 (Day 14), 1 (Day 19)
All survived
(b)
Usable dose range without
wreight loss (,Ig)
Cyclophosphamide 1000-5000
Melphalan 100-200
Chlorambucil 500-1000
" Safe " level
(fg)
500
50
200
* Single injection in 0-1 ml intraperitoneally.
Protection against tumour with druys alone
Some data were given previously for
protection of Balb/c mice against their
lymphoma SB1 (Davies and O'Neill,
1973). For EL4 an example is shown in
Fig. 1, using cyclophosphamide, where a
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Fie,. 1.- Protection of C57BL/6 mice against
EL4 lymphoma with cyclophosphamide in
4 (loses, first 18 h after challenge (5 x 104
cells) and then at 24 h intervals. Doses of
100 jig, A A; 200 ,ig, Fl Ol; 500
,ug, 0 0; control (buffered saline
injections), 0 O.
marked effect can be seen with an 18 h
time lapse. Data of this kind for each
drug were used to design the tests shown
below.
The " DRAB " (drug-antibody) effect
Cyclophosphamide. The test illustrat-
ed in Fig. 2 shows that an amount of
cyclophosphamide able to give a measur-
able degree of prolongation of life with
a time lapse (between challenge and
treatment) of 18 h (Fig. 1) gives no
effect if the time lapse is increased to
96 h. An amount of antibody was
given which also showed no effect alone
(this was calculated from data obtained
in previous experiments). When the same
dose of drug was followed an hour later
by the same dose of antibody, other
possible variables being held constant,
there was a modest but very definite
protective effect.
Chlorambucil.- When chlorambucil
was used at a comparable " safe " dose,
the same kind of effect was obtained and
is shown in Fig. 3. In this case a degree
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FI(e. 2. Protection of C57BL/6 mice agaioist EL4 as in Fig. 1 btut with cyclophosphamide (500 jig)
an(d tumouir specific anitiseruim (RI1 29/130 03 ml at I: 2 dilution). Treatmenit startedc 96 h after
ehallenige. Salinle controls, 0 O; anitiseruim alone, cyclophosphami(le aloine,
EC1C_; (irtrug followe(d 1 h later by anitiserlum, *- O.
DAYS
Fi'e. 3. Protection of C,57BL/6 mice against EL4 as irn Fig. 2 but
treatment starting 48 h after challenge. Saline controls, Q---
ambuicil, J J--E; (Irt1g followed I h later by anntiseruim, 0
of protection resuilts under the conditions
used, for both the drug and the antibody
independently, but using the same se-
quence of drug followed one hour later
by antibody a substantial amplification
is apparent, resuilting in permanent sur-
vival of more than half the challenged
mice in that group.
In a control series, a measurable but
relatively verv small effect could be
found when tumouir specific immuno-
globuilin was replaced by normal rabbit
w-ith chloratmnbtucil (200 pg) ani(t
- ; an-tiseruim, A ; chlor-
0.
serum (Fig. 4) with (1rg doses straddliing
the 0-2 mg used in the previous test.
Melphalan. When melphalan was
uise(I at the " safe " dose of 20 ,ug and
with a 48 h time lapse, but otherwise
under the same conditions as the previous
tests, the amplification over a very modest
effect of drug or antibody alone was so
marked that all mice in that group sur-
vived to a normal life span with no
tumour growth (Fig. 5).
C(1arcinoembryonic antibody. Three
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FiG. 4.-Normal rabbit sertum as a background for drug action in the protection of mice against
syngeneic tumour (EL4). Controls (saline alone), 0 O; chlorambucil alone (300 ,ug), A A;
chlorambucil followedl I h later by normal rabbit serum; clrug at 75 rig, [ O-; 150 ,g, * 0;
300 rig,A A.
100
D
80
060 X
40
20-
o ,V 10 i5 20 25 30 35 40
DAYS
FIG. 5. Protection of C57BL/6 mice against EL4 lymphoma with melphalan, showing total survival
against 10,000 lethal doses of EL4 cells and a 48 h time lapse before treatment. Controls (NRS),
Q 0; antiserum (0 5 ml of l: 2, i.p.), A A; melphalan (20 ,ug), dI ; drug followed
by antiserum 1 h later, * *.
rabbits were immunized by 6 weekly i.v.
injections of l mg in 0-2 ml of freeze dried
ascitic fluid from the growth of Ehrlich
ascites carcinoma in "A" strain mice.
Sample bleedings were tested by immuno-
diffusion against the homologous antigen
for anti-CEA and the most reactive
rabbit (R138) was used. The serum was
absorbed twice with 10 spleens/ml (for
2 h each time at 4°C) to remove all the
cytotoxicity for normal lymph node cells
and tested to show that antibody against
CEA, as seen by its immunodiffusion
line, remained in undiminished strength
after this absorption (Boyle, Davies and
Haughton, 1963; Haughton, 1962).
In a protection test (not illustrated),
this serum gave no protective effect to
C57BL/6 mice against EL4 under condi-
tions where R140 (an antiserum against
EL4) showed a substantial effect. A
sub-protective dose of chlorambucil gave
a negligible effect but amplified that of
serum R140. Drug followed by anti-CEA
had no effect (identical with normal
rabbit serum controls), showing that
anti-CEA is not able to collaborate in a
DRAB effect.
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;-. .-- I)rtug aintibo(ly sequence ani(l its reverse in protection of mice against syngeneic EL4 cells.
NRS coiitrols, --O; immtunoglobtulin (4 mg) aincd chlorambtucil (200 rig) I h later, A ;
the same buit (irmg followedl by immtunoglogtulin, A similar pair at IoNer (Irlig level
(1 00 /ug), immunoglobUlin followedl by drug, * *; (Irug follo-wed by immtuinoglobulli.l A A.
Order and timing. When EL4
Ig was uised fullY absorbed at a
of 4 mg/mouse, and chlorambuc
2 dose levels, 0-1 and 0 2 mg, t
preparations were given in the
drug-l h-antibody, and antibody-
drug. It will be seen from F
that in both comparable pairs of g
of mice, the order druig-antibody i
more effective one.
The effect of absorption. A bat
anti-EL4 rabbit serum was absort
times and samples kept from each
The cytotoxicity titres are show
Fig. 7 using normal C157BL/6 lyn
cytes and it can be seen that no reac
remnained after the thirdl absorl
S0 200 800 3200
Reciprocal of serum dilutions
Fi(,. 7. Complement medliate(l cytotoxici
of abbit, anti-EL4 serum, measured
ielease of 5'Cr from normal C57BL/6 lyml
no(le cells. The oIriginal titre, O(
after I absorption (10 spleens/m
AE- A; after 2, 3 i; after
* *.
xeno-
dose
il at
the 2
order
-1 h-
ig. 6
;roups
is the
there was, of course, residuial activity
for EL4 target cells. WTheni these sera
were tested for their protective capacity
in vivo, the results showed clearly that
absorption greatly affected the issue when
the total amouint of seruim given to each
grouip of mice was the same (Fig. 8).
DISCUSSION
The resuilts given in this paper are
ch of examples taken from an exteinsive series
)ed 3 of protection tests which serve to show a
stage. novel finding that a cytotoxic drug
Krn in followed by a tumour specific antibody
npho- provides treatment far more effective
tivity than can be achieved with either alone
?tion; (DRAB effect). The best combined effect
was obtained with the drugs which were
most effective alone, in the order mel-
phalan, chlorambucil, cyclophosphamide.
In the least effective situation of cyclo-
phosphamide, and with a time lapse of
96 h between challenge and treatment,
the DRAB effect was clear (Fig. 2,
line D) where neither drug nor antibody
had any measurable protective action
alone (lines B and C). In the most
effective combination using melphalan,
2800 all challenged mice resisted tumour growth
when the time lapse before treatment
by extended as far as 48 h (Fig. 5, line D).
ph There is an extensive literature on
D); passive immunotherapy in animal models l). and on combinations of various kinds
(e.g. Arai, Wallace and Blakemore, 1973),
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Fi(,. 8. Effect of absorption on effectiveness of antiserum (0.5 ml of 1 2) in protection of C57BL/6
mice againist EL4 lymphoma when amplified by chlorambucil (200 /Lg) given 1 h earlier. Anti-
serum unabsorbed, A A; once absorbed, O C; 3 times absorbed, 0 0 ; controls
(normal serum alone), 0 .O
but not of drugs with tuimour specific
antisera. There exist claims to " pois-
oned arrows ", e.y. chlorambucil linked to
tumour specific sera (Ghose et al., 1972)
but the effects claimed are likely to be
due to the DRAB effect we now describe
(see Davies and O'Neill, 1 973; O'Neill,
Pearson and Davies, 1974).
A slight buit measurable benefit found
with (Irug an(i normal rabbit serum may
be due to the direct toxicity of most
rabbit sera for mice. In any event,
wTith tumour antisera a (legree of speci-
ficity for effects on tumour cells rather
than host cells is evident, and presumably
follows on the absorption of antibody
against normal tissue. This very labori-
ous absorption has a further and unex-
pected influence, in that the effectiveness
of DRAB is very much dependent on
this absorption (Fig. 8) and therefore
some interference with protection results
from the presence of antibody against
normal mouse tissues.
The tests using antibody one hour
after drug administration have had the
most favourable outcome but a series
of protection tests designed to clarify the
ideal sequence and timing have given
some confusing results and will be re-
ported on when better clarified.
From the practical point of view, it
is important to discover what kind of
antigens expressed by tumours are candi-
dates for production of antibody to
obtain a DRAB effect. We have taken
advaintage of the tumour specific antigen
of EL4 cells (Gorer and Amos, 1956)
which is the cell surface expressed charac-
ter distinguishing this carcinogen induced
lymphoma from its host's tissues (Davies,
1963; Davies et al., 1974a). This suggests
that for human patients a serum may
need to be raised for each individual.
On the other hand, cross-reactions are
well known between tumours in certain
classes. Thus for example, a series of
goat anti-human melanoma sera, after full
absorption with human spleens until
non-cytotoxic for normal human lympho-
cytes, reacted with cells of a cultured
human melanoma cell line (O'Neill, to
be published). Whether such a cross-
reactive antibody would serve to take
part in a DRAB effect remains to be
seen, but using the more widely cross-
reacting mouse CEA (carcinoembryonic
antigen) as immunogen, the strongly
reactive antiserum remaining after absorp-
tion with normal tissue failed to show
any collaboration with chlorambucil in
protection of mice against their syngeneic
tumour.
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